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Abstract 
Background: Nasopharyngeal carcinoma (NPC) shows a high proportion of lymph node metastasis, and treatment 
guidelines have been developed for positive nodes. However, no irradiation guidelines have been proposed for 
patients with enlarged neck lymph nodes (ENLNs) that do not meet the radiological criteria of 10 mm in diameter for 
positive lymph nodes. This study aimed to determine the prognostic value and radiation dose for ENLNs in N0‑cate‑
gory NPC patients treated with intensity‑modulated radiotherapy (IMRT).
Methods: We reviewed the medical data of 251 patients with non‑metastatic, N0‑category NPC treated with IMRT. 
Receiver operating characteristic curves were used to calculate the cut‑off value of the ENLN diameter for the prediction of 
disease failure. The biological equivalent dose (BED) for ENLNs was calculated. Patient survival was compared between the 
small and large ENLN groups. Independent prognostic factors were identified using the Cox proportional hazards model.
Results: The estimated 4‑year regional relapse‑free survival rate was higher in patients with ENLNs ≥5.5 mm than 
in those with ENLNs <5.5 mm (100% vs. 98.8%, P = 0.049), whereas disease‑free, overall, and distant metastasis‑free 
survival rates were similar between the two groups. After adjusting for various factors, ENLN diameter was not identi‑
fied as an independent prognostic factor (P > 0.05 for all survival rates). In the subgroup analysis, patients receiving 
BED ≥72 Gy had a similar prognosis as patients receiving BED <72 Gy in both the small and large ENLN groups. The 
multivariate analysis also confirmed that BED ≥72 Gy was not associated with significantly improved prognosis in 
patients with N0‑category NPC.
Conclusions: A BED of 72 Gy to ENLNs is considerably sufficient to provide a clinical benefit to patients with N0‑cate‑
gory NPC. Prospective studies are warranted to validate the findings in the present study.
Keywords: Nasopharyngeal carcinoma, N0‑category, Enlarged neck lymph node, Biological equivalent dose, 
Intensity‑modulated radiotherapy, Prognosis
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Background
Nasopharyngeal carcinoma (NPC), a cancer arising from 
the nasopharyngeal epithelium, has an extremely unbal-
anced geographical distribution with an age-standardized 
incidence of 20–50 per 100,000 males in South China 
compared to 0.5 per 100,000 in predominantly white 
populations of European origin [1]. Due to the difficulty 
of radical resection and the high degree of radiosensitivity 
of NPC, radiotherapy has been the primary and only cura-
tive treatment for non-disseminated NPC. Chemotherapy 
has also been reported to provide a survival benefit to 
patients with advanced NPC [2]. For patients with lymph 
node (LN)-positive NPC, concurrent chemoradiotherapy 
(CCRT) alone or combined with neoadjuvant/adjuvant 
chemotherapy has been recommended as the standard 
treatment according to the National Comprehensive Can-
cer Network (NCCN) clinical practice guidelines [3].
NPC has a high proportion of LN metastasis (86.4%) [4], 
and the NCCN guidelines recommend a prescribed dose 
of 66–70 Gy to treat positive LNs. However, no irradiation 
guidelines have been proposed for patients with enlarged 
neck LNs (ENLNs) that do not meet the radiological crite-
ria of 10 mm in diameter for positive LNs [5]. Indeed, it is 
difficult to assess the nature of such ENLNs because NPC 
is typically treated using radiotherapy without perform-
ing cervical nodal biopsies. In clinical practice, this issue 
remains controversial as many clinicians concern that these 
ENLNs may be positive and adversely affect prognosis. 
However, other clinicians have considered ENLNs to be 
negative and treat these tumors with a low prescribed radi-
ation dose. This situation urgently needs to be addressed.
To the best of our knowledge, no studies to date have 
investigated the prognostic value of ENLNs in patients 
with N0-category NPC treated with intensity-modulated 
radiotherapy (IMRT). Therefore, we conducted a ret-
rospective study to characterize this issue and provide 
clinical evidence to help clinicians guide the treatment of 
NPC in such situations.
Methods
Ethical agreement
The present study was approved by the Research Eth-
ics Committee of Sun Yat-sen University Cancer Center 
(Guangzhou, China), and informed consent was obtained 
from all patients for the use of their data in clinical 
researches. The present study was conducted in accord-
ance with the ethical standards of the institution.
Patient selection
The data of patients with newly-diagnosed, non-dissem-
inated NPC treated between November 2009 and Febru-
ary 2012 at Sun Yat-sen University Cancer Center were 
reviewed. Pre-treatment magnetic resonance imaging 
(MRI) data on the nasopharyngeal and cervical regions 
were thoroughly analyzed. The eligibility criteria were 
as follows: (1) N0-category disease; (2) World Health 
Organization (WHO) pathologic type II/III; and (3) age 
of 18 years or older.
Clinical staging
The routine staging process included a complete history 
collection and clinical examination of the head and neck 
region, direct fiberoptic nasopharyngoscopy, MRI scans 
of the skull base, neck and chest radiography, a whole-
body bone scan, and abdominal sonography. Positron 
emission tomography (PET)-computed tomography (CT) 
scans were also performed when clinically indicated. All 
patients received a dental evaluation before radiotherapy.
All cases were restaged according to the 7th edition of 
the International Union against Cancer/American Joint 
Committee on Cancer (UICC/AJCC) system [6]. All MRI 
materials and clinical records were reviewed to mini-
mize heterogeneity in restaging. Two radiologists (L.Z.L 
and L.T) separately evaluated all the scans, and disagree-
ments were resolved by consensus.
MRI protocol
All patients underwent MRI using a 3-Tesla system (Trio 
Tim; Siemens, Erlangen, Germany). The region from the 
suprasellar cistern to the inferior margin at the sternal 
end of the clavicle was examined using a head-and-neck 
coil. T1-weighted fast spin-echo images on the axial, 
coronal, and sagittal planes (repetition time [TR]/echo 
time [TE], 650/9 ms), T2-weighted fast spin-echo images 
on the axial plane (TR/TE, 2470/90 ms), and a spin-echo 
echo-planar DWI sequence (matrix, 192 × 192; TR/TE, 
5100/96  ms; b values, 0 and 1000  s/mm2; three signal 
averages) were obtained before contrast injection. After 
the intravenous administration of gadopentetate dimeg-
lumine (0.1 mmol/kg body weight; Magnevist, Schering, 
Berlin, Germany), axial and sagittal T1-weighted spin-
echo sequences and coronal T1-weighted fat-suppressed 
spin-echo sequences were performed sequentially using 
the same parameters as applied before the injection of 
gadopentetate dimeglumine. Subsequently, 5-mm-thick 
sections were obtained with a 1-mm interslice gap for 
the axial plane, and 6-mm-thick sections with a 1-mm 
interslice gap were obtained for the coronal and sagittal 
planes, resulting in a matrix size of 512 × 512.
Measurement of the short diameter of the ENLNs
T2-weighted axial MRI data without contrast enhance-
ment were reviewed. The short diameters of the ENLNs 
were measured separately by two radiologists with experi-
ence of more than 10 years. Disagreements were resolved 
by consensus. For patients with two or more ENLNs, the 
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short diameter of the largest ENLN was measured. The 
maximum short diameter should be ≤10 mm for ENLNs 
of level IIa and ≤9 mm for ENLNs of other levels.
Clinical treatment
Radiotherapy
All patients underwent IMRT at Sun Yat-sen Univer-
sity Cancer Center. Immobilization was achieved using 
a custom-made head-to-neck thermoplastic cast with 
the patient’s neck resting on a support. High-resolution 
planning CT scans with contrast were taken from the 
vertex to 2 cm below the sternoclavicular joint at a slice 
thickness of 3  mm. The target volumes were delineated 
slice-by-slice on treatment planning CT scans using an 
individualized delineation protocol according to the 
International Commission on Radiation Units and Meas-
urements reports 50 and 62. All targets were treated 
using the simultaneous integrated boost technique. The 
biological equivalent dose (BED) for the ENLNs was cal-
culated using the following formula: 
 with nd represents the total radiation dose, d represents 
fraction dose, α/β represents the biological effect of tumor 
cells to radiation (the value for tumor tissues is 10) [7].
Chemotherapy
According to our institutional guidelines, prior to com-
mencing the treatment, we recommended radiother-
apy alone for stage I disease, CCRT for stage II disease, 
and CCRT alone or in combination with neoadjuvant/
adjuvant chemotherapy for stage III to IVA-B disease. 
Neoadjuvant or adjuvant chemotherapy regimen com-
prised cisplatin (80 mg/m2 on day 1) with 5-fluorouracil 
(750 mg/m2 on days 1–5) or cisplatin (75 mg/m2 on day 
1) with docetaxel (75 mg/m2 on day 1) every 3 weeks for 
two or three cycles. Concurrent chemotherapy regimen 
comprised cisplatin (30–40  mg/m2 on day 1) adminis-
tered every week or cisplatin (80–100  mg/m2 on day 1) 
on weeks 1, 4, and 7 of radiotherapy.
Follow‑up and statistical analysis
Patient follow-up was measured from the first day of 
therapy to the last visit (August 8, 2016) or death. The 
patients were examined at least every 3 months dur-
ing the first 2 years and every 6 months thereafter until 
death. The end-points (time to first defining event) were 
regional relapse-free survival (RRFS, time to regional 
node recurrence), disease-free survival (DFS, time to dis-
ease recurrence or death), overall survival (OS, time to 
death from any cause), and distant metastasis-free sur-
vival (DMFS, time to distant metastasis); local relapse-
free survival (LRFS) was not assessed in the present 
BED = nd × (1+ d/[α/β]),
study. RRFS was the primary end-point of the present 
study.
Receiver operating characteristic (ROC) curves were 
used to calculate the cut-off value of the ENLN diameter 
for the prediction of DFS. The cut-off value of serum lac-
tate dehydrogenase (LDH) level was determined as pre-
viously described [8, 9]. The Chi square test was used to 
compare clinical characteristics. Life-table estimation 
was performed using the Kaplan–Meier method and 
log-rank test. The multivariate Cox proportional hazards 
model was used to estimate the hazard ratio (HR) and 
95% confidence interval (CI). All statistical tests were 
two-sided; P  <  0.05 was considered significant. STATA 
statistical package (STATA 12; StataCorp LP, College Sta-
tion, Texas, USA) was used for all analyses.
Results
ENLN diameter
A total of 1811 patients were diagnosed with non-dis-
seminated NPC at Sun Yat-sen University Cancer Center 
between November 2009 and February 2012, and 251 
(13.9%) were selected in the present study. The median 
diameter of the largest ENLN for the 251 patients was 
6  mm (range, 3–10  mm). Based on an analysis of the 
ROC curve (Fig. 1), the cut-off value of the ENLN diam-
eter for the prediction of DFS was 5.5  mm (area under 
the curve [AUC], 0.569; sensitivity, 0.773; specificity, 
0.349). Therefore, patients were divided into small and 
large ENLN groups using this cut-off value: 85 (33.9%) 
Fig. 1 Receiver operating characteristic curve analysis of the short 
diameter of the largest enlarged neck lymph node (ENLN) in patients 
with N0‑category nasopharyngeal carcinoma (NPC) for the prediction 
of disease‑free survival. AUC area under the curve
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patients had ENLN  <5.5  mm, and 166 (66.1%) patients 
had ENLN ≥5.5 mm in the short diameter.
Baseline characteristics and radiation dose
Of the 251 patients, 194 (77.3%) were males, and 57 
(22.7%) were females, with a male-to-female ratio of 3.4:1. 
The median age was 46  years (range, 19–77  years). The 
small and large ENLN groups were similar in terms of host 
factors, tumor stage, and treatment (all P > 0.05) (Table 1).
The prescribed doses were 66–72  Gy at 2.12–2.43  Gy/
fraction to the planning target volume (PTV) of the pri-
mary gross tumor volume (GTVnx), 50–68  Gy at 1.67–
2.27  Gy/fraction to the PTV of the ENLN (GTVnd), 
60–63 Gy to the PTV of the high-risk clinical target vol-
ume (CTV1), and 50–56  Gy to the PTV of the low-risk 
clinical target volume (CTV2). The median BED to GTVnd 
was 72.0  Gy (range, 58.3–83.4  Gy) for the entire cohort, 
72.0 Gy (range, 58.3–83.4 Gy) for the small ENLN group, 
and 72.0  Gy (range, 58.3–82.0  Gy) for the large ENLN 
group. The BED was not significantly different between the 
small and large ENLN groups (t test, P = 0.418).
Treatment failure patterns
Up to the last follow-up (August 8, 2015), 16 (6.4%) patients 
were lost to follow-up. The median follow-up duration 
was 49.3 months (range, 11.0–67.7 months) for the entire 
cohort and 49.8 months (range, 11.3–67.7 months) for the 
surviving patients. In total, 10 (4.0%) patients developed 
local recurrence, 2 (0.8%) experienced regional recurrence, 
and 12 (4.8%) suffered distant metastasis. Moreover, 12 
cancer-related deaths were observed. The failure patterns 
in the two groups are summarized in Table 2.
Univariate and multivariate analysis
For the entire cohort, the estimated 4-year RRFS, DFS, 
OS, and DMFS rates were 99.6, 91.4, 95.3, and 95.2%, 
respectively. For patients in the large and small ENLN 
groups, except for the estimated 4-year RRFS rate (100% 
vs. 98.8%, P = 0.049; Fig. 2a), the estimated 4-year DFS 
(89.4% vs. 95.2%, P = 0.246; Fig. 2b), OS (94.8% vs. 96.4%, 
P  =  0.572; Fig.  2c), and DMFS rates (93.9% vs. 97.6%, 
P  =  0.199; Fig.  2d) were comparable. Moreover, the 
4-year RRFS (100% vs. 99.4%, P = 0.278), DFS (95.4% vs. 
89.1%, P = 0.062), OS (97.7% vs. 94.0%, P = 0.311), and 
DMFS rates (97.8% vs. 93.7%, P = 0.147) were also com-
parable between patients receiving BED < and ≥72 Gy.
Table 1 Baseline characteristics of  the 251 patients with   
N0-category nasopharyngeal carcinoma (NPC) and enlarged 
neck lymph nodes (ENLNs)
The patients were divided into small and large ENLN groups using the cut-off 
value (5.5 mm) of the short diameter of the largest ENLN for the prediction of DFS
LDH lactate dehydrogenase, BED biological equivalent dose
a P values were calculated using the Chi square test or Fisher’s exact test if 
indicated
b According to the 7th edition of the American Joint Committee on Cancer/
Union for International Cancer Control (AJCC/UICC) staging system
Character‑
istic








 Male 194 66 (77.6) 128 (77.1)
 Female 57 19 (22.4) 38 (22.9)
Age (years) 0.661
 <50 167 55 (64.7) 112 (67.5)
 ≥50 84 30 (35.3) 54 (32.5)
Smoking 0.935
 Yes 73 25 (29.4) 48 (28.9)
 No 178 60 (70.6) 118 (71.1)
Drinking 0.836
 Yes 25 8 (9.4) 17 (10.2)
 No 226 77 (90.6) 149 (89.8)
LDH (U/L) 0.973
 <245 242 82 (96.5) 160 (96.4)




 Yes 87 26 (30.6) 61 (36.7)
 No 164 59 (69.4) 105 (63.2)
BED (Gy) 0.821
 <72 91 30 (35.3) 61 (36.7)




 Yes 152 47 (55.3) 105 (63.3)
 No 99 38 (44.7) 61 (36.7)
T categoryb 0.270
 T1 80 27 (31.8) 53 (31.9)
 T2 54 24 (28.2) 30 (18.1)
 T3 87 25 (29.4) 62 (37.3)
 T4 30 9 (10.6) 21 (12.7)
Table 2 Failure patterns in  the small and  large ENLN 
groups of NPC patients
a P values were calculated using Chi square test or Fisher exact test if indicated
b One patient died without disease recurrence and distant metastasis
c Three patients experienced both local and distant failure







Local recurrence 0 (0) 10 (6.0) 0.049
Regional recurrence 2 (2.3) 0 (0) 0.217
Total locoregional failure 2 (2.3) 10 (6.0) 0.328
Distant metastasis 2 (2.3) 10 (6.0) 0.328
Total death 3 (3.5) 9 (5.4) 0.725
Total failure 5 (5.9)b 17 (10.2)c 0.248
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Multivariate analysis was performed to adjust for vari-
ous factors, including gender, age, smoking, drinking, 
serum LDH level, family history of cancer, BED, chemo-
therapy, T category, and ENLN diameter. Both ENLN 
diameter and BED were not established as independ-
ent prognostic factors for RRFS, DFS, OS, or DMFS (all 
P > 0.05). Moreover, no significant prognostic factor was 
identified for RRFS (Table 3).
Subgroup analysis
Furthermore, we conducted a stratified analysis to char-
acterize the prognostic value of different BED in the 
small and large ENLN groups. The estimated 4-year 
RRFS, DFS, OS, and DMFS rates were comparable 
between patients receiving a BED ≥72 Gy and <72 Gy in 
both the small ENLN group (Fig. 3) and the large ENLN 
group (Fig. 4).
Discussion
In the present study, we found that ENLN diameter was 
not an independent prognostic factor for patients with 
N0-category NPC and ENLN and that a BED  ≥72  Gy 
to the ENLNs was not associated with significantly 
prolonged RRFS, DFS, OS, or DMFS in both small and 
large ENLN groups. Moreover, consistent with previous 
results [8, 9], LDH was the most important predictor of 
DFS, OS, and DMFS.
Previous studies reported that 13.6% [4] and 15% [10] 
of patients with NPC had no lymph node metastasis, 
similar to the results of the present study (13.9%). In the 
cohort examined in the present study, tumor stage and 
treatment-related factors were well balanced between 
the small and large ENLN groups, and univariate analy-
sis revealed that the 4-year RRFS rate was significantly 
higher in the small ENLN group than in the large ENLN 
group (P =  0.049). However, after adjusting for various 
factors, multivariate analysis did not establish ENLN 
diameter as an independent predictor of RRFS. There are 
three potential reasons that may explain this result. First, 
the ENLNs are pathologically negative and have no prog-
nostic impact. Second, the radiation dose received by the 
ENLNs may be sufficient to provide a radical treatment 
effect and, therefore, result in a satisfactory prognosis. 
Third, the relatively small sample size of each group may 
have resulted in a low statistical power. Indeed, reflect-
ing the excellent regional control rates, no independent 
Fig. 2 Kaplan–Meier survival curves of patients with N0‑category NPC and ENLN in the small ENLN (<5.5 mm) and large ENLN (≥5.5 mm) groups. 
a Regional relapse‑free survival; b disease‑free survival; c overall survival; d distant metastasis‑free survival. NPC nasopharyngeal carcinoma, ENLN 
small neck lymph node








































































































































































































































































































































































































































































































































































































































































































































































































































Page 7 of 9Peng et al. Chin J Cancer  (2017) 36:32 
predictor was identified for RRFS among this cohort of 
patients with N0-category NPC.
Notably, the retropharyngeal small LNs were not ana-
lyzed in the present study because they are adjacent 
to the primary tumor and are often treated as part of 
the primary tumor volume, even if they do not fit the 
diagnostic criteria for positive LNs in clinical practice. 
Therefore, almost all negative retropharyngeal small 
LNs received a radical radiation dose, which would have 
affected the results of the present study if these nodes 
were included in the analysis. A comparison of the failure 
patterns between groups revealed that the large ENLN 
group had a significantly higher rate of local failure than 
the small ENLN group. However, local relapse-free sur-
vival (LRFS) was not assessed as an endpoint in the pre-
sent study because the ENLNs would not affect the local 
control. Therefore, we did not perform univariate analy-
sis of the LRFS for the two groups.
Many studies have solely focused on the feasibility of 
omitting irradiation to the lower neck in N0-category 
NPC [11–14]. However, no studies have investigated 
the optimal radiation dose for the ENLNs. Notably, the 
doses prescribed to the ENLNs greatly varied in the 
present study, and the highest dose was 68 Gy—the radi-
cal radiation dose for positive LNs. This finding reflects 
clinicians’ concern that the ENLNs may be positive and 
could adversely affect prognosis, and should, therefore, 
receive a radical radiation dose. Subgroup analysis was 
conducted to further investigate the prognostic value of 
the BED for patients in different ENLN groups to estab-
lish the optimal BED for the ENLNs. We found that 
patients receiving a BED ≥72 Gy had a similar prognosis 
to patients receiving a BED <72 Gy in both the small and 
large ENLN groups, indicating that a total BED of 72 Gy 
may be sufficient for the ENLNs. Moreover, Li et al. [14] 
also revealed that the administration of 60 Gy in 30 frac-
tions (BED  =  72  Gy) to the suspicious node area did 
not lead to cervical node relapse, further supporting the 
results obtained in the present study. This finding should 
be of great importance to clinicians when devising indi-
vidualized treatment strategies.
Based on the results of the present study, we provide 
credible evidence to reassure clinicians that the ENLNs 
do not negatively affect the prognosis of patients with 
N0-category NPC in the era of IMRT if a total BED 
of 72  Gy is achieved. The BED for the treatment of the 
Fig. 3 Kaplan–Meier survival curves of N0‑category NPC patients in the small ENLN group stratified by a biological equivalent dose 
(BED) < or ≥72 Gy. a Regional relapse‑free survival; b disease‑free survival; c overall survival; d distant metastasis‑free survival. NPC nasopharyngeal 
carcinoma, ENLN enlarged neck lymph node
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ENLNs should not exceed 72  Gy, as excessive radiation 
doses will cause acute toxicities, such as radiation-related 
dermatitis, and severe long-term toxicities, such as neck 
muscle atrophy [15].
Several limitations exist in the present study. First, 
the follow-up duration may be insufficient to observe a 
significant difference of OS since patients with N0-cate-
gory disease had excellent prognoses. Therefore, we set 
RRFS as the first endpoint to address this issue because 
a median follow-up of 49.3  months was sufficient to 
determine the difference in RRFS. Second, the assess-
ment of the ENLNs could only be performed reliably 
using MRI because, unlike other head and neck can-
cers, NPC is typically treated without pathologic anal-
ysis of the ENLNs. Third, the sample size and number 
of regional failure events in each group were relatively 
small. Moreover, due to incomplete medical records, 
several other important prognostic factors, including 
plasma Epstein-Barr virus DNA [16–22] and primary 
tumor volume [23, 24], could not be assessed in the 
present study. Therefore, further prospective clinical 
studies with larger cohorts that include additional prog-
nostic factors are warranted to confirm the outcomes of 
the present study.
Conclusions
The present retrospective study provides evidence sug-
gesting the treatment of patients with N0-category NPC 
and ENLNs. A total BED of 72 Gy to the ENLNs is con-
siderably sufficient to provide a clinical benefit, and 
excessive radiation doses could be avoided to reduce 
acute and long-term toxicities. However, prospective 
randomized studies are warranted to validate the findings 
obtained in the present study.
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